MX2016011174A - Peptidos y metodos de uso. - Google Patents

Peptidos y metodos de uso.

Info

Publication number
MX2016011174A
MX2016011174A MX2016011174A MX2016011174A MX2016011174A MX 2016011174 A MX2016011174 A MX 2016011174A MX 2016011174 A MX2016011174 A MX 2016011174A MX 2016011174 A MX2016011174 A MX 2016011174A MX 2016011174 A MX2016011174 A MX 2016011174A
Authority
MX
Mexico
Prior art keywords
peptides
subject
protein
methods
inhibit
Prior art date
Application number
MX2016011174A
Other languages
English (en)
Inventor
Scheiflinger Friedrich
Dockal Michael
Osterkamp Frank
Polakowski Thomas
Hartmann Rudolf
Paschke Matthias
Hartlieb Bettina
Original Assignee
3B Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3B Pharmaceuticals Gmbh filed Critical 3B Pharmaceuticals Gmbh
Publication of MX2016011174A publication Critical patent/MX2016011174A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La invención proporciona péptidos, incluyendo péptidos que se enlazan y, opcionalmente, inhiben a la Proteína S, y composiciones de los mismos. Los péptidos se pueden utilizar, por ejemplo, para inhibir la actividad de la Proteína S, mejorar la formación de trombina en un sujeto, aumentar la formación de coágulos de sangre en un sujeto, tratar un trastorno de la coagulación de la sangre en un sujeto, purificar la Proteína S, e identificar un compuesto que se enlace a la Proteína S.
MX2016011174A 2014-02-28 2015-02-27 Peptidos y metodos de uso. MX2016011174A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461946103P 2014-02-28 2014-02-28
PCT/US2015/018041 WO2015131061A1 (en) 2014-02-28 2015-02-27 Peptides and methods of use

Publications (1)

Publication Number Publication Date
MX2016011174A true MX2016011174A (es) 2016-11-15

Family

ID=52633723

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011174A MX2016011174A (es) 2014-02-28 2015-02-27 Peptidos y metodos de uso.

Country Status (16)

Country Link
US (2) US9447147B2 (es)
EP (1) EP3110841B1 (es)
JP (1) JP6711761B2 (es)
KR (1) KR20160126075A (es)
CN (1) CN106232615B (es)
AU (1) AU2015222846B2 (es)
BR (1) BR112016019484A2 (es)
CA (1) CA2939658C (es)
EA (1) EA201691749A1 (es)
ES (1) ES2873956T3 (es)
IL (1) IL247448B (es)
MX (1) MX2016011174A (es)
PH (1) PH12016501608A1 (es)
SG (2) SG10201807066UA (es)
WO (1) WO2015131061A1 (es)
ZA (1) ZA201605518B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021226243A1 (en) * 2020-05-05 2021-11-11 Vega Therapeutics, Inc. Protein s antibodies, methods of making and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321123A (en) * 1991-07-02 1994-06-14 The Scripps Research Institute Protein S polypeptides and anti-peptide antibodies that inhibit protein S binding to C4B binding protein, diagnostic systems and therapeutic methods
SE9604378D0 (sv) * 1996-11-27 1996-11-27 Tac Ab Methods and reagents for determining protein S
EP1446152A1 (en) * 2001-11-09 2004-08-18 Novo Nordisk A/S Pharmaceutical composition comprising factor vii polypeptides and protein s inhibitors
KR101784030B1 (ko) * 2010-03-19 2017-10-10 백스터 인터내셔널 인코포레이티드 Tfpi 저해제 및 사용 방법
WO2011125015A2 (en) * 2010-04-05 2011-10-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
CN104302306B (zh) 2012-03-21 2019-03-22 百深有限责任公司 Tfpi抑制剂及其使用方法
CN104211799B (zh) * 2013-05-29 2017-12-26 成都渊源生物科技有限公司 人源egf结构域蛋白及其应用

Also Published As

Publication number Publication date
IL247448A0 (en) 2016-11-30
CN106232615B (zh) 2021-06-01
BR112016019484A2 (pt) 2017-10-24
US20170035835A1 (en) 2017-02-09
ZA201605518B (en) 2018-12-19
CN106232615A (zh) 2016-12-14
US9447147B2 (en) 2016-09-20
US20150246947A1 (en) 2015-09-03
CA2939658C (en) 2022-10-04
EP3110841A1 (en) 2017-01-04
IL247448B (en) 2022-09-01
WO2015131061A1 (en) 2015-09-03
EP3110841B1 (en) 2021-03-31
JP2017509602A (ja) 2017-04-06
EA201691749A1 (ru) 2016-12-30
JP6711761B2 (ja) 2020-06-17
SG10201807066UA (en) 2018-09-27
PH12016501608A1 (en) 2016-10-03
CA2939658A1 (en) 2015-09-03
US10124033B2 (en) 2018-11-13
AU2015222846A1 (en) 2016-08-25
SG11201607067TA (en) 2016-10-28
AU2015222846B2 (en) 2019-09-19
KR20160126075A (ko) 2016-11-01
ES2873956T3 (es) 2021-11-04

Similar Documents

Publication Publication Date Title
WO2017015622A3 (en) Gdf11 binding proteins and uses thereof
PH12016501644B1 (en) Binding proteins and methods of use thereof
EA201791093A1 (ru) Антитела к cd47, способы и применение
MX2022001043A (es) Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas.
MX2017010734A (es) Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos.
SA518390944B1 (ar) أجسام مضادة لمثبط مسار عامل نسيج واستخداماتها
NZ709059A (en) Immunotherapy with binding agents
NZ701121A (en) Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
MX2018000590A (es) Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79).
EA201591762A1 (ru) Человеческие антитела к grem1
IN2014DN06792A (es)
HK1260897A1 (zh) 使用四氫異喹啉小分子來結合並調節pcsk9的蛋白活性的組合物和方法
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2022000242A (es) Anticuerpos contra ticagrelor y metodos de uso.
WO2013142153A3 (en) Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
PH12016501608A1 (en) Peptides and methods of use
MX2020013410A (es) Proteinas prohemostaticas para el tratamiento de hemorragias.
MX2018004228A (es) Anticuerpo que se une especificamente a erbb3 y uso de este.
EA201790790A1 (ru) Антитела человека против vegfr-2/kdr
MA40363A (fr) Agents de liaison de rspo1 et leurs utilisations
EA201501176A1 (ru) Замещенные бензоксазолы
EA202090453A3 (ru) Антитела к cd40